ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 1403 • ACR Convergence 2024

    Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center

    MANJIT SALUJA1 and ARVIND CHOPRA2, 1CENTER FOR RHEUMATIC DISESAES, Pune, Maharashtra, India, 2CENTER FOR RHEUMATIC DISEASES, Pune, Maharashtra, India

    Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during  standard care (including QOL). Alternatively, these concerns are important components…
  • Abstract Number: 1598 • ACR Convergence 2024

    Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling

    Naomi Patel1, Aaron Wu1, Shruthi Srivatsan1, Eli Miloslavsky2, Peter Merkel3, John Stone4, Hyon K. Choi5, Emily Hyle1 and Zachary Wallace2, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Newton, MA, 3University of Pennsylvania, Philadelphia, PA, 4Massachusetts General Hospital , Harvard Medical School, Concord, MA, 5Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
  • Abstract Number: 2163 • ACR Convergence 2024

    Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App

    Marc Blanchard1, Cinja Koller2, Patrick Hermann1, Johanna Mettler1, Tiffany Prétat3, Pedro Ming Azevedo3 and Thomas Hügle3, 1Lausanne University Hospital, Lausanne, Vaud, Switzerland, 2Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, 3Lausanne University Hospital, Lausanne, Switzerland

    Background/Purpose: Mobile health apps have demonstrated effectiveness in managing chronic musculoskeletal pain syndromes such as fibromyalgia. We developed an app called POCOS for chronic musculoskeletal…
  • Abstract Number: 2375 • ACR Convergence 2024

    Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?

    Burak Kundakci1, Megan Barber2, Ann E. Clarke2, Sindhu Johnson3, Ian Bruce1 and On behalf of the revised SLE organ damage index (SDI) collaborators4, 1Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 2Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4University of Manchester, Manchester, United Kingdom

    Background/Purpose: The Systemic Lupus International Collaborating Clinics (SLICC), Lupus Foundation of America (LFA), and American College of Rheumatology (ACR) are leading a global initiative to…
  • Abstract Number: 0155 • ACR Convergence 2024

    Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients

    Fizza Zulfiqar1, Morgan Steele2, Sharanya Shre Ezhilarasan Santhi3, Bryanna Singh2, Jaisal Brar3, Sumit Raut3, Prami Nakarmi3, Samhitha Bitla Reddy3, Ojo Ayomide3, Bashar Roumia3, Fariha Tareen3, Nathan Crook3, Vanessa Drust3, Ahmed Fawzy Mohamed3, Asad Mohammad Jani3, Jennifer Orejuela3, Siena Captain3, Nikhil Vojalla3, Muhammad Bilal4, Rida Fatima4, Sanjana Kesireddy3, Paige Misner3, Rishab Prabhu3, Camelia Arsene3, Jawad Bilal5 and Jacky Duong3, 1Trinity Health Oakland/Wayne State University, Pontiac, MI, 2Trinity Health Oakland, Pontiac, MI, 3Trinity Health Oakland, Pontiac, 4Bassett Medical Center, Cooperstown, NY, 5Southeast Tucson, Clinician Rheumatologist, Tuscon

    Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…
  • Abstract Number: 0398 • ACR Convergence 2024

    Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data

    Mary Eckert1, Eveline Wu2, Melissa Oliver3, Joshua Scheck4, Sivia Lapidus5, Ummusen Kaya Akca6, Shima Yasin7, Aleksander Lenert8, Sara Stern9, Antonella insalaco10, Manuela Pardeo10, Gabriele Simonini11, Edoardo Marrani12, Xing Wang13, Bin Huang14, Leonard Kovalick15, Natalie Rosenwasser16, Erin Balay-Dustrude17, Gabriel Casselman16, Liau Adriel18, Ava Klein18, Yurong Shao4, Claire Yang4, Molly Briggs4, Emily Deng4, Iris Hamilton4, Ethan Mueller16, Elise Machrone4, Paige Trunnel4, Doaa Mosa19, Lori Tucker20, Hermann Girschick21, Ronald Laxer22, Georgina Tiller23, Jonathan Akikusa24, Christian Hedrich25, Karen Onel26, Fatma Dedeoglu27, Marinka Twilt28, Seza Ozen29, Polly Ferguson30, Laura Schanberg31, Bryce Reeve32 and Yongdong (Dan) Zhao33, 1Seattle Children's, Mercer Island, WA, 2University of North Carolina School of Medicine, Chapel Hill, NC, 3Indiana University, Indianapolis, IN, 4Seattle Children's Hospital, Seattle, 5Hackensack University Medical Center, Montclair, NJ, 6Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 7University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, 8University of Iowa, Iowa City, IA, 9University of Utah, Salt Lake City, UT, 10IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 11Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 12University of Florence, Firenze, Florence, Italy, 13Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, 14Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 15UNC Health Care, Durham, NC, 16Seattle Children's Hospital, Seattle, WA, 17University of Washington, Seattle, WA, 18Seattle Children’s Research Institute, University of Washington, Seattle, 19Mansoura University Hospital, Mansoura City, Egypt, 20BC Children's Hospital, Vancouver, BC, Canada, 21Vivantes Clinic Friedrichshain, Wuerzburg, Germany, 22SickKids, Toronto, ON, Canada, 23University of British Columbia - Vancouver, Vancouver, BC, Canada, 24Royal Children's Hospital, Parkville, Victoria, Australia, 25University of Liverpool, Liverpool, United Kingdom, 26HSS, New York, NY, 27Boston Children's Hospital, Boston, MA, 28Alberta Children's Hospital, Calgary, AB, Canada, 29Department of Pediatrics, Hacettepe University, Ankara, Turkey, 30University of Iowa Carver College of Medicine, Iowa City, IA, 31Duke University Medical Center, DURHAM, NC, 32Duke University School of Medicine, Durham, 33University of Washington, Redmond, WA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
  • Abstract Number: 0619 • ACR Convergence 2024

    Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus

    OKEOGHENE AKPOIGBE1, BETTINA ESCOLANO2, ENOCH J ABBEY2 and Amanda Sammut3, 1New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, 2New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, 3New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
  • Abstract Number: 0739 • ACR Convergence 2024

    One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic

    Patricia Harkins1, Sharon Cowley2, Robert Harrington3, seoidin McKittrick4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3St. James's Hospital, Dublin, Dublin, Ireland, 4University of Limerick, Limerick, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

    Background/Purpose: To date the longitudinal outcomes of those with isolated Polymyalgia Rheumatica (PMR) are poorly understood, owing largely to the fact that in the majority…
  • Abstract Number: 1051 • ACR Convergence 2024

    Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis

    Daniel Labson1, Qian Cai2, Concetta Crivera3 and Federico Zazzetti4, 1Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, 2Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, 3Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, 4Johnson & Johnson Innovative Medicine, Horsham, PA, PA

    Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune conditions primarily characterized by muscle weakness and inflammation. Real-world evidence on economic outcomes of patients with…
  • Abstract Number: 1428 • ACR Convergence 2024

    A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)

    Wolfgang Hueber1, Raphaele Seror2, Raphael Porcher3, Gabriel Baron4, Linchen He5, Wen-Lin Luo5, Xavier Mariette6 and Peter Gergely1, and the members of the NECESSITY IMI2 consortium, 1Novartis Pharma, Basel, Switzerland, 2Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 3Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 4Hôpitaux Universitaires Paris-Sud (AP-HP), Paris, Ile-de-France, France, 5Novartis Pharma, East Hanover, NJ, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren’s disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase…
  • Abstract Number: 1617 • ACR Convergence 2024

    Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission

    Luigi Boiardi1, Pierluigi Macchioni1, Francesco Muratore2, Chiara Marvisi1, Caterina Ricordi1, Annibale Versari1, Giulia Besutti1, Lucia Spaggiari1, Stefania Croci1 and Carlo Salvarani1, 1Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, 2Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
  • Abstract Number: 2169 • ACR Convergence 2024

    Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study

    Paul Studenic1, Nadine Schwab2, Günther Zauner2, Thi Lan Vi Tran3 and Helga Lechner-Radner4, 1Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria, Vienna, Austria, 2dwh GmbH, simulation services, Vienna, Austria & Institute of Information Systems Engineering, TU Wien, Vienna, Austria, 3Medical University of Vienna, Vienna, Austria, 4Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria

    Background/Purpose: In patients with rheumatoid arthritis (RA), we often see a disconnect between patient and evaluator perceived disease activity. In this study we aim to…
  • Abstract Number: 2377 • ACR Convergence 2024

    Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY

    Anitha Ramu1, Justina Shafik2, Maedeh Ashrafi3, Juliann Allen2, Kiera Brennan1 and Noa Schwartz4, 1Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Jacobi Medical Center, Bronx, NY, 4Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Studies have demonstrated that socioeconomic status (SES) significantly influences outcomes of patients with SLE.1 Traditionally, tools such as income, education, occupation, and housing have…
  • Abstract Number: 0187 • ACR Convergence 2024

    Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
  • Abstract Number: 0402 • ACR Convergence 2024

    Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts

    Mariana Correia Marques1, Erin Balay-Dustrude2, Claudia Bracaglia3, Marinka Twilt4, Karen Onel5, Simone Appenzeller6, Fatma Dedeoglu7, Esraa Eloseily8, Penelope Martinez Jimenez9, Rebecca Trachtman10, Francesca Minoia11 and Susan Shenoi12, and on behalf of the MAS/sJIA WP of PReS and CARRA sJIA Workgroup, 1National Institutes of Health, Bethesda, MD, 2University of Washington, Seattle, WA, 3IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 4Alberta Children's Hospital, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada, Calgary, AB, Canada, 5HSS, New York, NY, 6Department of Orthopedics, Rheumatology and Traumatology. University of Campinas, Campinas, Brazil, 7Boston Children's Hospital, Boston, MA, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Icahn School of Medicine at Mount Sinai- Elmhurst Hospital Center, Rego Park, NY, 10Icahn School of Medicine at Mount Sinai, New York, NY, 11Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 12Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

    Background/Purpose: Multinational research is essential to globally improve the management of systemic juvenile idiopathic arthritis (sJIA), improve recognition of rare complications like lung disease, and…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology